

Hikma is a global pharmaceutical company listed on the London Stock Exchange providing customers across North America, MENA and Europe with a broad range of generic, specialty and branded pharmaceutical products. In KSA, Hikma is a leading provider of high-quality medicines serving healthcare professionals and patients across the Kingdom for over 40 years.



Local expertise, global strength



3
Manufacturing plants



740+
Employees



1
R&D centre in Riyadh

Making healthcare accessible for all

We ensure our world-class medicines are within reach for all, improving access to healthcare in the Kingdom

Manufacturing high-quality medicines

Our three manufacturing plants produce essential medicines in key therapeutic areas:

- General formulation plant**
Manufactures a wide range of medicines in various dosage forms
- Penicillin plant**
Manufactures high-quality penicillin-based anti-infectives
- Cephalosporin plant**
Manufactures high-quality cephalosporin based anti-infectives

Hikma in KSA is **ranked #1 among the pharmaceutical companies based on sales**¹

Hikma has a **5.8% market share** of the total Saudi pharmaceutical market¹

One of the **leading exporting pharmaceutical companies** in KSA

1st Saudi manufacturing facility to receive US FDA approval

A diversified portfolio of medicines

We offer patients lives in the Kingdom over 214 medicines covering 15 therapeutic areas to address a wide range of healthcare needs:



Anti-infectives



Oncology



Autoimmune



Diabetes



Central Nervous System



Cardiovascular



Gastrointestinal



Respiratory



Dermatology



Others

Highly-specialised commercial team of 250+ commercial representatives providing unsurpassed market access

Fully-owned distribution centre reaching different areas of the Kingdom from city hospitals to remote polyclinics to retail pharmacies

Reference:
1. Based on internal analysis by Hikma Pharmaceuticals PLC using data from the following source: IQVIA MIDAS® Quarterly value sales data for the countries listed below for the period :MAT Aug. 2024. Market definitions: Includes all therapeutic areas except for those ATC-3 classes that may encompass Nutrients, Infant Formulas, and Diagnostics elements within MIDAS Data, specifically ATCs SIT, T1G, T2X, T3A, V6C, and V6D, in each case reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.